Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease.
Blood
; 143(10): 866-871, 2024 Mar 07.
Article
de En
| MEDLINE
| ID: mdl-38118071
ABSTRACT
ABSTRACT Pyruvate kinase (PK) is a key enzyme in glycolysis, the sole source of adenosine triphosphate, which is essential for all energy-dependent activities of red blood cells. Activating PK shows great potential for treating a broad range of hemolytic anemias beyond PK deficiency, because they also enhance activity of wild-type PK. Motivated by observations of sickle-cell complications in sickle-trait individuals with concomitant PK deficiency, activating endogenous PK offers a novel and promising approach for treating patients with sickle-cell disease.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Pyruvate kinase
/
Erreurs innées du métabolisme du pyruvate
/
Anémie hémolytique congénitale non sphérocytaire
/
Drépanocytose
Limites:
Humans
Langue:
En
Journal:
Blood
Année:
2024
Type de document:
Article
Pays d'affiliation:
Moldavie
Pays de publication:
États-Unis d'Amérique